Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has announced the initiation of clinical development for its next-generation amylin receptor agonist ASC36 and the dual-target agonist ASC35, both designed for monthly administration, targeting obesity treatment [1] Group 1: Clinical Development - ASC36 and ASC35 are expected to enter clinical trials, with the company planning to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 [1] - The company believes that ASC36 and ASC35 have the potential to achieve more significant weight loss effects in obese populations compared to monotherapy, based on promising preclinical data [1] Group 2: Company Insights - Dr. Wu Jinzi, the founder, chairman, and CEO of the company, highlighted the increasing evidence supporting the company's platform technology in designing, optimizing, and developing multiple long-acting peptide formulations for monthly subcutaneous injection [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has announced the initiation of clinical development for its next-generation amylin receptor agonist ASC36 and the dual-target GLP-1R/GIPR agonist ASC35 combination formulation, both designed for monthly administration. The company plans to submit an Investigational New Drug (IND) application to the FDA for these treatments aimed at obesity in the second quarter of 2026 [1]. Group 1 - The ASC36 and ASC35 combination formulations are expected to provide more significant weight loss effects in obese populations compared to monotherapy [1]. - The founder and CEO of the company, Dr. Wu Jinzi, highlighted the encouraging preclinical data supporting the potential of these formulations [1]. - The company has demonstrated its capability in designing, optimizing, and developing multiple long-acting peptide injections for monthly subcutaneous administration [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：1672） 自願性公告 歌禮宣布每月一次新一代胰淀素受體激動劑ASC36和每月一次新一代 GLP-1R/GIPR雙靶點激動劑ASC35的複方製劑進入臨床開發階段 1 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） － 在非人靈長類動物的頭對頭研究中，每月一次皮下給藥的胰淀素(amylin)受 體激動劑多肽ASC36和每月一次皮下給藥的GLP-1R/GIPR雙靶點激動劑多肽 ASC35複方製劑的藥代動力學特徵與ASC36和ASC35單獨給藥時相當。該複 方製劑利用歌禮專有的超長效藥物開發平台(ULAP)技術開發而成。 － 在頭對頭飲食誘導肥胖 (DIO) 大鼠研究中，ASC36 單藥的減重效果較 eloralintide單藥相對提升約32%，而在頭對頭DIO小鼠研究中，ASC35單藥的 減重效果較替爾泊肽單藥相對提升約71%。 － 在頭對頭 DIO ...

每经AI快讯，歌礼制药-B(01672.HK)尾盘涨超7%，截至发稿，涨7.05%，报11.08港元，成交额5993.81 万港元。 ...

Core Viewpoint - The company, Gilead Sciences-B (01672), has seen a significant stock increase of over 7% following the announcement of its potential "best-in-class" monthly subcutaneous injection amylin receptor agonist, ASC36, as a clinical development candidate [1] Group 1: Company Developments - Gilead has selected ASC36 as a candidate for clinical development, with plans to submit a new drug clinical trial application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is designed to have a longer apparent half-life and higher bioavailability per milligram of peptide, enabling monthly subcutaneous administration [1] - The CEO, Dr. Wu Jinzi, indicated that ASC36's preclinical characteristics suggest it may achieve best-in-class efficacy and a more patient-friendly dosing titration scheme [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 7% following the announcement of a new clinical development candidate, ASC36, which is a potential "best-in-class" once-monthly subcutaneous amylin receptor agonist for obesity treatment [1] Company Summary - Gilead Sciences has selected ASC36 as a clinical development candidate, with plans to submit a new drug clinical trial application to the FDA in the second quarter of 2026 [1] - ASC36 is designed to have a longer apparent half-life and higher bioavailability per milligram of peptide, enabling once-monthly subcutaneous administration [1] - The CEO, Dr. Wu Jinzi, indicated that ASC36's preclinical characteristics suggest it may achieve best-in-class efficacy and a more convenient dosing regimen, potentially leading to superior weight loss effects and a patient-friendly titration scheme [1] Market Activity - As of the report, Gilead Sciences-B's stock increased by 7.05%, reaching HKD 11.08, with a trading volume of HKD 59.9381 million [1]

港股探底回升，恒生指数、恒生科技指数再度转涨。小鹏汽车-W大涨17%，瑞浦兰钧涨近10%，歌礼制 药-B涨超7%。 来源：滚动播报 ...

Core Insights - Pfizer won a dramatic bidding war against Novo Nordisk for the weight loss drug manufacturer Metsera, acquiring it for $10 billion, which includes a competitive amylin drug pipeline [3][4] - Amylin drugs mimic the action of the pancreatic hormone amylin, differing from currently marketed GLP-1 drugs, but both types suppress appetite and reduce food intake [3][4] - Analysts believe that the future combination of GLP-1 and amylin therapies could enhance weight loss efficiency and quality [4][5] Industry Developments - Major pharmaceutical companies, including Novo Nordisk, Eli Lilly, AbbVie, and Roche, are developing amylin-targeting weight loss drugs [4][6] - Eli Lilly's amylin therapy, eloralintide, showed positive results in a mid-stage study, indicating potential for further development [4][5] - Novo Nordisk presented data at the 2025 EASD annual meeting showing that its amylin drug cagrilintide led to an average weight loss of approximately 12.5 kg in obese or overweight patients [5][6] Competitive Landscape - Roche has partnered with Zealand Pharma to develop long-acting amylin drugs, indicating a collaborative approach in the industry [6] - Experts suggest that while direct comparisons between GLP-1 and amylin therapies are not yet possible, they may offer different benefits for various patient populations [6] - In China, several biopharmaceutical companies are also developing next-generation amylin-targeting weight loss therapies, with notable advancements from companies like Genscript and Xianju Pharmaceutical [6]

Core Insights - Pfizer has acquired Metsera for $10 billion, which includes a competitive amylin drug pipeline, highlighting the intense competition in the weight loss drug market [1] - Amylin drugs mimic the action of the pancreatic hormone amylin, differing from GLP-1 drugs, but both aim to suppress appetite and reduce food intake [1] - Amylin receptor has been confirmed as an effective drug target, with amylin mimetics emerging as new therapies for obesity and diabetes [1] Group 1 - Major pharmaceutical companies, including Novo Nordisk, Eli Lilly, AbbVie, and Roche, are developing amylin-targeting weight loss drugs [2] - Eli Lilly's amylin therapy, eloralintide, showed positive results in a mid-stage study, helping obese or overweight patients lose over 20% of their weight in 48 weeks [2] - Novo Nordisk presented data on cagrilintide, showing an average weight loss of approximately 12.5 kg in a phase III trial for non-diabetic obese patients [2] Group 2 - Roche has partnered with Zealand Pharma to develop long-acting amylin drugs [3] - Experts suggest that while direct comparisons between GLP-1 and amylin therapies are not yet possible, they may offer different benefits for various patient populations [3] - Several domestic biopharmaceutical companies are also developing next-generation amylin-targeting weight loss therapies, with Gilead Sciences selecting ASC36 as a clinical candidate [3]

Core Insights - The article highlights the transformative journey of Gilead Sciences (1672.HK) in the Chinese biotech industry, showcasing its resilience and strategic decision-making in the face of challenges [2][11] - Gilead's shift towards a differentiated pipeline in weight loss drugs has led to a significant market re-evaluation and recovery in its stock price [4][9] Group 1: Company Development - Gilead Sciences was listed on the Hong Kong Stock Exchange in August 2018 at an initial price of 14 HKD, reaching a market capitalization of 16 billion HKD, but faced a decline due to setbacks in its core hepatitis C drug [3][4] - By August 2024, the company's stock price had plummeted to 0.76 HKD, resulting in a market value reduction of over 95% [3][4] - The founder, Dr. Wu Jinzi, demonstrated strategic foresight by pivoting the company's focus to the metabolic disease sector, particularly the weight loss drug market, starting in 2022 [3][5] Group 2: Strategic Shift and Market Response - Following the strategic shift, Gilead's stock price surged from 0.76 HKD in August 2024 to 18.75 HKD by August 2025, representing an increase of over 20 times and restoring its market capitalization to the billion HKD level [4][9] - The market's positive response reflects recognition of Gilead's research team's capabilities and strategic execution [4][9] Group 3: R&D and Competitive Advantage - Gilead has adopted a differentiated approach in drug development, focusing on oral small molecule GLP-1 receptor agonists and ultra-long-acting formulations, rather than following mainstream peptide drug development paths [5][8] - The core pipeline, ASC30, has shown promising clinical results, with a maximum weight reduction of 6.5% in U.S. Phase Ib trials, and is expected to complete Phase IIa trials by the end of the year [5][6] - Gilead is also developing ASC35 and ASC36, which are expected to provide significant advantages in terms of dosing frequency and efficacy compared to existing treatments [6][7] Group 4: Global Competitiveness and Valuation - Despite the stock price recovery, Gilead's current market capitalization is still considered undervalued compared to global peers, as evidenced by recent acquisition bids for similar companies [9][10] - Gilead's diverse pipeline, including multiple formulations with the potential for monthly and quarterly dosing, positions it favorably in the competitive landscape [9][10] Group 5: Lessons and Implications for the Industry - Gilead's successful transformation underscores the importance of strong R&D leadership and strategic vision in navigating industry challenges [11] - The case of Gilead serves as a valuable reference for other Chinese biotech companies seeking to innovate and compete on a global scale [11]